SANTA CRUZ, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing led by The Venture Collective (TVC), with participation from argenx, Droia Ventures and existing investors Merck Global Health Innovation Fund, Artis Ventures, and First Spark Ventures.

The funding will support development of the company's proprietary drug discovery platform and advance its pipeline of macrocyclic peptide therapeutics designed to address historically difficult-to-drug or "undruggable" targets.

Last month, Unnatural Products announced a licensing agreement with Novartis to develop macrocyclic peptide therapeutics for historically undruggable cardiovascular targets, including up to $100 million upfront and up to $1.7 billion in total potential milestones.

"Macrocyclic peptides represent a powerful new therapeutic modality," said Cameron Pye, Chief Executive Officer and ...